Intelligence Feed event · Equity · 2026-08-03

    Curium to Acquire Lantheus in $8.0 Billion Radiopharm Deal

    Question

    Curium to Acquire Lantheus in $8.0 Billion Radiopharm Deal

    Direct answer

    The $102.50 cash offer represents a definitive exit for Lantheus shareholders, with the CVRs providing potential upside based on diagnostic or therapeutic milestones. This merger consolidates the radiopharmaceutical market, a niche that has seen increasing interest from large-cap pharma.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Curium to Acquire Lantheus in $8.0 Billion Radiopharm Deal”, revision 1, evidence through 2026-08-03. https://marketontology.com/market-events/2026-08-03/curium-to-acquire-lantheus-in-8-0-billion-radiopharm-deal-f65e92

    EQUITY
    Curium to Acquire Lantheus in $8.0 Billion Radiopharm Deal
    The $102.50 cash offer represents a definitive exit for Lantheus shareholders, with the CVRs providing potential upside based on diagnostic or therapeutic milestones. This merger consolidates the radiopharmaceutical market, a niche that has seen increasing interest from large-cap pharma.
    LNTH
    Impact
    81
    AUG 3
    SIG
    100%
    LNTH
    Curium to Acquire Lantheus in $8.0 Billion Radiopharm Deal
    The $102.50 cash offer represents a definitive exit for Lantheus shareholders, with the CVRs providing potential upside based on diagnostic or therapeutic milestones. This merger consolidates the radiopharmaceutical market, a niche that has seen increasing interest from large-cap pharma.
    → M&A activity driving sector consolidation and immediate price action in LNTH.
    Impact
    The $102.50 cash offer represents a definitive exit for Lantheus shareholders, with the CVRs providing potential upside based on diagnostic or therapeutic milestones. This merger consolidates the radiopharmaceutical market, a niche that has seen increasing interest from large-cap pharma.
    Affected
    LNTH
    Transmission
    M&A activity driving sector consolidation and immediate price action in LNTH.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month